The invention relates to a pharmaceutical composition comprising a modified Xa factor (GDXa), said modified GDXa being non- thrombogenic and able to bind to the TFPI but not to the phospholipids, for preventing or treating a hemorrhagic accident in a patient suffering from haemophilia A or B with or without inhibitor.